ACADIA PHARMACEUTICALS INC 4
4 · ACADIA PHARMACEUTICALS INC · Filed Nov 26, 2014
Insider Transaction Report
Form 4
Mills Roger
Executive VP, Development
Transactions
- Exercise/Conversion
Common Stock
2014-11-26+25,000→ 43,550 total - Exercise/Conversion
Stock Option (right to buy)
2014-11-26−25,000→ 139,035 totalExercise: $1.55Exp: 2020-03-11→ Common Stock (25,000 underlying) - Sale
Common Stock
2014-11-26$30.09/sh−25,000$752,265→ 18,550 total
Footnotes (4)
- [F1]Includes 916 shares acquired on November 29, 2013 and 1,859 shares acquired on May 30, 2014 by Dr. Mills under the ACADIA Pharmaceuticals Employee Stock Purchase Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2014.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.18 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- [F4]25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.